Evidence map›Paper›PMID 31557128›Full record

ArticleAging2019

Up regulation of Rho-associated coiled-coil containing kinase1 (ROCK1) is associated with genetic instability and poor prognosis in prostate cancer.

Stefan Steurer, Benjamin Hager, Franziska Büscheck, Doris Höflmayer, Maria Christina Tsourlakis, Sarah Minner, Till S Clauditz, Claudia Hube-Magg, Andreas M Luebke, Ronald Simon and 11 more

Open access · greenAbstract read
In one paragraph

Article in Aging, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 25 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Long non-coding RNA PVT1 facilitates cell migration and invasion by regulating miR-148a-3p and ROCK1 in breast cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 4 institutions in 1 country.

Stefan SteurerInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Benjamin HagerInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Franziska BüscheckInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Doris HöflmayerInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Maria Christina TsourlakisInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Sarah MinnerInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Till S ClauditzInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Claudia Hube-MaggInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Andreas M LuebkeInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Ronald SimonInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Jakob R IzbickiGeneral, Visceral and Thoracic Surgery Department and Clinic, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Eike BurandtInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Guido SauterInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Christoph FrauneInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Sören WeidemannInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Thorsten SchlommDepartment of Urology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Hans HeinzerMartini-Clinic, Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Alexander HaeseMartini-Clinic, Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Markus GraefenMartini-Clinic, Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Hartwig HulandMartini-Clinic, Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Asmus HeumannGeneral, Visceral and Thoracic Surgery Department and Clinic, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Universität Hamburg · DEUniversity Medical Center Hamburg-Eppendorf · DEMartini-Klinik · DECharité - Universitätsmedizin Berlin · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesOverexpression of the cytoskeleton-modulating kinase ROCK1 has been associated with unfavorable outcome in many cancers, but its impact in prostate cancer is largely unknown.

resultsA weak ROCK1 staining was found in >90% of normal, and cancerous prostate tissues, but was generally stronger in cancer cells as compared to adjacent normal glands. In cancer, ROCK1 staining was considered weak, moderate, and strong in 22%, 53%, and 18% of cases respectively. Higher ROCK1 expression levels were associated with tumor stage, and Gleason grade, positive nodal stage, positive surgical margin, accelerated cell proliferation and early PSA recurrence in multivariable analysis. ROCK1 up regulation was associated with androgen receptor (AR) expression,

conclusionsThis study identifies ROCK1 expression associated with prognosis in prostate cancer.

methodsWe tested ROCK1 expression in 12 427 prostate cancer specimens and followed PSA recurrence after prostatectomy.

Indexed as

Up-RegulationAdenocarcinomaBiomarkers, TumorGene Expression Regulation, NeoplasticHumansMaleNeoplasm GradingOncogene FusionPrognosisProstateProstatic NeoplasmsReceptors, Androgenrho-Associated KinasesSurvival RateBiomarkers, TumorReceptors, Androgenrho-Associated KinasesROCK1 protein, humanimmunohistochemistryprognosisprostate cancerROCK1tissue micro array

Identifiers

PMID31557128
PMCPMC6781985
OpenAlexW2975102425

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.